Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.

Preeclampsia Clinical Trial

— PRE-EVE  

Official title:

Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04846686
• Other study ID #: IRBN622021/CHUSTE
• Status: Completed
• Start date: June 1, 2022
• Est. completion date: January 1, 2023

Study information

• Verified date: June 2023
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors. A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: January 1, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.
• For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia
• For the control group: patient who had a normal pregnancy

Exclusion Criteria:

• Patient who gave birth naturally
• Underage patients or under guardianship
• Patients who do not speak or read French
• Childbirth under X

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia

Intervention

Biological:
• Placenta pathological examination
a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.

Locations

Country	Name	City	State
France	Chu Saint-Etienne	Saint-Étienne

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne	Commissariat A L'energie Atomique

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry	Measured by placenta pathological examination (immunohistochemistry technical).	At delivery
Primary	Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry	Measured by placenta pathological examination (immunohistochemistry technical).	At delivery
Secondary	Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry	Measured by placenta pathological examination (immunohistochemistry technical).	At delivery
Secondary	Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry	Measured by placenta pathological examination (immunohistochemistry technical).	At delivery
Secondary	Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry	Measured by placenta pathological examination (immunohistochemistry technical).	At delivery
Secondary	Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical).	Measured by placenta pathological examination (immunohistochemistry technical).	At delivery
Secondary	Presence of at least one chronic maternal pathologies describe below	diabetes, hypertension, kidney disease, Systemic Lupus Erythematosus (SLE), antiphospholipid syndrome	At delivery
Secondary	Obstetric history	Pre-Eclampsia (PE) and intra uterine growth retardation (IUGR), term of onset and severity of Pre-Eclampsia (PE)	At delivery
Secondary	Presence of an anticoagulant treatment	treatment by aspirin or Heparin or low molecular weight heparins (LMWH)	At delivery